Leiden, The Netherlands, Oct. 3, 2013 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical
company focusing on RNA-modulating therapeutics for rare diseases
with high unmet need, will hold a conference call on Tuesday,
October 8, 2013 at 11:00 a.m. ET / 5:00 p.m. CET to discuss
recently-presented data on drisapersen, an investigational
antisense oligonucleotide, for the treatment of Duchenne Muscular
Dystrophy (DMD) patients with an amenable mutation, which is
exclusively licensed to GlaxoSmithKline (GSK).
Prosensa Chief Executive Officer Hans Schikan will be joined by
Giles Campion, Prosensa's Chief Medical Officer & Senior
Vice-President of Research and Development and Judith van Deutekom,
Vice President of Drug Discovery to discuss the recently presented
results from studies of drisapersen. These include results from
DEMAND III (Phase III; DMD114044); DEMAND II (Phase II; DMD114117);
DEMAND V (Phase II; DMD114876) and 177 week data from the Phase
I/II extension study (DMD114673).
The data were presented at the DIA/FDA Oligonucleotide based
Therapeutics Conference in Washington DC, the 18th World Muscle
Society Congress in Asilomar, California and the 9th Annual Meeting
of the Oligonucleotide Therapeutics Society in Naples, Italy,
running from Sept 25-27, October 1-5 and 6-8, respectively.
In order to participate in the conference call, please dial
1-877 280 2342 (US domestic) and refer to
conference ID 2579927. International dial-in
numbers and an audio webcast can be accessed under "Events &
Presentations" through the Investors & Media section of the
Prosensa corporate website www.prosensa.com.
Drisapersen, (previously GSK2402968/PRO051) an
antisense oligonucleotide, which induces exon skipping of exon 51,
is currently in late stage development for DMD.
GSK obtained an exclusive worldwide license to
develop and commercialize drisapersen from Prosensa in 2009.
Drisapersen has been designated orphan drug status in the EU, US
and Japan. In June 2013, drisapersen was granted Breakthrough
Therapy designation by the US Food and Drug Administration.
For more information regarding the ongoing
clinical studies involving drisapersen visit www.clinicaltrials.gov.
Duchenne Muscular Dystrophy (DMD) is a severely
debilitating childhood neuromuscular disease that affects up to 1
in 3,500 live male births. This rare disease is caused by mutations
in the dystrophin gene, resulting in the absence or defect of the